Five Key Advances in Infectious Disease Drug Development
Infectious diseases contribute to approximately 25% of global mortality and present critical healthcare challenges, especially in under-resourced countries. Recent research and development...
View ArticleBehind the Scenes with Kits & Logistics for Vaccine Studies
Whether large or small, vaccine studies differ from standard drug development in many ways. Sarah Slette, Sr. Study Manager, Vaccines & Novel Immunotherapeutics, explains the unique challenges her...
View ArticleNovel Assays Support RSV Drug and Vaccine Development
Chances are you’ve been hit by the respiratory syncytial virus (RSV), which infects nearly everyone by the age of 2 and usually reinfects exposed people throughout their lifetimes. While most healthy...
View ArticleStepping Up the Game: Measles, Mumps, Rubella and Varicella (MMRV)...
The introduction of vaccines against Measles, Mumps, Rubella (MMR), and Varicella (the “V” in MMRV vaccines) led to a drop in the incidence of these diseases by 89% (Varicella) and 99% (MMR). These...
View ArticleELISPOT Assay: A Powerful Tool in Vaccine Development and Immune Monitoring
Over the past several years, the scientific community has made tremendous progress in advancing our understanding of the immune system, from the basic functions of its various components to molecular...
View ArticleELISPOT Addresses the Complex Questions Arising From Vaccine and Novel Therapies
The accelerated arrival of novel vaccines and immunotherapies into the clinical space spurred the emergence of fields like personalized medicine, immuno-profiling and immuno-monitoring built around...
View ArticleThe promise of vaccines for fighting C. difficile
Over the last decade, Clostridium difficile (C. difficile) infection has rapidly become more prevalent. C. difficile, often abbreviated as C. diff, usually spreads through hospitals and other...
View Article
